Phibro Animal Health (NASDAQ:PAHC) Upgraded at StockNews.com

StockNews.com upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a buy rating to a strong-buy rating in a report issued on Saturday.

PAHC has been the topic of a number of other reports. Barclays boosted their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Morgan Stanley boosted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Finally, JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC opened at $20.61 on Friday. The stock has a market cap of $834.77 million, a P/E ratio of 47.93, a P/E/G ratio of 0.58 and a beta of 0.53. The firm’s 50-day simple moving average is $23.01 and its 200 day simple moving average is $21.01. Phibro Animal Health has a fifty-two week low of $10.03 and a fifty-two week high of $25.98. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th were issued a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.33%. Phibro Animal Health’s dividend payout ratio is 111.63%.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Brandes Investment Partners LP raised its stake in shares of Phibro Animal Health by 1.2% during the 2nd quarter. Brandes Investment Partners LP now owns 2,405,629 shares of the company’s stock worth $40,521,000 after purchasing an additional 29,071 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Phibro Animal Health by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 775,470 shares of the company’s stock worth $13,005,000 after purchasing an additional 42,086 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Phibro Animal Health by 6.3% during the second quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock valued at $12,027,000 after buying an additional 42,299 shares in the last quarter. Dana Investment Advisors Inc. lifted its position in shares of Phibro Animal Health by 17.2% in the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock worth $8,619,000 after buying an additional 75,546 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Phibro Animal Health by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock worth $11,430,000 after acquiring an additional 27,201 shares in the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.